Company PledPharma AB (publ) Nasdaq Stockholm

Equities

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Sector Bio Therapeutic Drugs

Inactive Instrument

End-of-day quote Nasdaq Stockholm Other stock markets
- ^SEK	-

22/02	Egetis Therapeutics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI
22/02	Egetis Therapeutics AB Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Egetis Therapeutics AB (publ), formerly PledPharma AB (publ) is a Sweden-based pharmaceutical drug development company, focusing on projects in late-stage development for treatment of diseases with unmet medical needs in the orphan drug segment. The Companyâs pipeline include Emcitate developed for the treatment of MCT8 deficiency, PledOx developed to reduce nerve damage associated with chemotherapy and Aladote developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning.

SEK in Million	2021	Weight	2022	Weight	Delta
Emcitate 97.3 %	16	40.9 %	22	97.3 %	+39.92%
PledOx 2.7 %	23	59.1 %	1	2.7 %	-97.34%

SEK in Million	2021	Weight	2022	Weight	Delta
Other Countries 19.9 %	6	15.0 %	5	19.9 %	-21.49%
France 17.3 %	3	7.6 %	4	17.3 %	+33.52%
Spain 15.0 %	3	7.6 %	3	15.0 %	+17.48%
United Kingdom 11.1 %	3	7.3 %	3	11.1 %	-10.10%
Italy 9.7 %	-	-	2	9.7 %	-
Sweden 8.4 %	1	3.5 %	2	8.4 %	+43.50%
Australia 8.4 %	-	-	2	8.4 %	-
Poland 7.5 %	-	-	2	7.5 %	-
Japan 2.7 %	23	59.1 %	1	2.7 %	-97.34%

Managers	Title	Age	Since
Nicklas Westerholm CEO	Chief Executive Officer	48	16/17/16
Yilmaz Mahshid DFI	Director of Finance/CFO	45	31/17/31
Marianne Berrens-Peijnenburg CTO	Chief Tech/Sci/R&D Officer	-	05/22/05
Anna Sjögren CTO	Chief Tech/Sci/R&D Officer	56	-
Kristina Nygren CTO	Chief Tech/Sci/R&D Officer	63	01/21/01
Katayoun Welin-Berger CTO	Chief Tech/Sci/R&D Officer	56	01/23/01
Henrik Krook COO	Chief Operating Officer	51	06/20/06
Peder Sven Walberg BRD	Director/Board Member	50	01/20/01
Karl Hård IRC	Investor Relations Contact	62	01/22/01
Nils Hallén HRO	Human Resources Officer	56	01/23/01

Members of the board	Title	Age	Since
Mats Blom BRD	Director/Board Member	59	01/21/01
Peder Sven Walberg BRD	Director/Board Member	50	01/20/01
Thomas Lönngren CHM	Chairman	73	01/21/01
Gunilla Christina Osswald BRD	Director/Board Member	63	01/17/01
Lena Elisabeth Svanberg BRD	Director/Board Member	63	01/17/01

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	292,571,459	212,443,237 ( 72.61 %)	0	72.61 %

Name	Equities	%	Valuation
Peder Sven Walberg 11.54 %	33,776,221	11.54 %	21 M kr
Peter Lindell 8.784 %	25,700,000	8.784 %	16 M kr
Avla Holding AB 6.039 %	17,668,330	6.039 %	11 M kr
Frazier Life Sciences Management LP 5.816 %	17,017,220	5.816 %	11 M kr
Handelsbanken Fonder AB 4.630 %	13,546,283	4.630 %	8 M kr
Flerie Invest AB 4.539 %	13,280,571	4.539 %	8 M kr
RegulaPharm AB 3.600 %	10,531,660	3.600 %	7 M kr
LINC AB 2.574 %	7,532,021	2.574 %	5 M kr
Unionen (Investment Management) 1.689 %	4,942,499	1.689 %	3 M kr
Carl Rosvall 1.203 %	3,520,287	1.203 %	2 M kr

Egetis Therapeutics AB

Klara Norra Kyrkogata 26

111 22, Stockholm

+46 86 79 72 10

http://www.egetis.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs